Compare StocksCRM vs MRNA

Salesforce, Inc. (CRM) vs Moderna, Inc. (MRNA): Which Is the Better Buy in 2026?

As of 2026-06-19, CRM is undervalued at $152, with a DCF intrinsic value of $274 and a margin of safety of 45%. MRNA is overvalued at $64, with an intrinsic value of $6 and a margin of safety of -963%. Of the two, CRM has the wider margin of safety.

CRM
Salesforce, Inc.
$151.78
VS
MRNA
Moderna, Inc.
$63.96

Rewards

CRM
  • Gross margin of 77.6% indicates strong pricing power — typical of businesses with significant intellectual property or brand strength.
  • Free cash flow has grown at a 31.6% CAGR over the past 4 years, demonstrating strong earnings power growth.
  • Each dollar of retained earnings has created $5.53 of earning power — management is an exceptional capital allocator.
MRNA

    Risks

    CRM
      MRNA
      • ROIC has declined by 67.4 percentage points over the past 4 years, which may signal competitive erosion.
      • Gross margin of -69.9% is low, suggesting a competitive or commodity-like market with limited pricing power.
      • Moderna, Inc. scores only 17/100 on the Economic Moat Score, suggesting limited durable competitive advantages.

      Key Valuation Metrics

      Learn more →
      CRM
      MRNA
      Valuation
      $16.55B
      Free Cash Flow
      $-20.00M
      13.32%
      FCF Yield
      -0.08%
      17.57
      Trailing P/E
      N/A
      9.77
      Forward P/E
      -15.21
      Quality & Moat
      9.61%
      ROIC
      -26.47%
      16.91%
      ROE
      -36.56%
      77.64%
      Gross Margin
      -69.89%
      0.77
      PEG Ratio
      N/A
      Balance Sheet Safety
      0.90
      Net Debt / Equity
      Net cash
      N/A
      Interest Coverage
      N/A
      2.38
      Net Debt / EBITDA
      N/A
      1.09%
      Dividend Yield
      0.00%
      CRM: 6Ties: 1MRNA: 2
      CRMMRNA

      Historical Fundamentals

      Learn more →
      CRM

      Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

      MRNA

      Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

      Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

      $1 Retained Earnings Test

      Learn more →
      CRM
      $-7.99
      created per $1 retained over 3 years
      Market Cap Declined
      Σ Retained
      $14.67B
      Δ Market Cap
      $-117.14B
      Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
      > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
      MRNA
      N/A
      Net losses over 3 years — test not applicable
      Company had negative cumulative retained earnings
      Σ Retained
      $-11.10B
      Δ Market Cap
      $-57.53B
      Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
      > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

      Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
      > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

      Discounted Cash Flow (DCF) Analysis

      Learn more →
      CRM
      44.5% Margin of Safety
      Price is 44.5% below estimated fair value
      Current Price: $151.78
      Fair Value: $273.71
      Strongly undervalued
      Undervalued
      Fairly valued
      Overvalued
      Strongly overvalued
      MRNA
      962.8% Overvalued
      Price is 962.8% above estimated fair value
      Current Price: $63.96
      Fair Value: $6.02
      Strongly undervalued
      Undervalued
      Fairly valued
      Overvalued
      Strongly overvalued

      Reverse DCF — Market-Implied Growth

      Learn more →
      CRM

      What growth rate is the market pricing in at $152?

      +3.6%
      Market-Implied Owner Earnings Growth
      Standard FCF implies -2.8%

      The market implies +3.6% Owner Earnings growth, below historical trends — potential opportunity.

      Standard FCF implies a more demanding -2.8%, reflecting heavy growth investment expected to generate future returns.

      MRNA

      Requires positive FCF to compute implied growth rate.

      Economic Moat Score

      Learn more →
      CRM
      58/100
      Narrow Moat
      70+ Wide · 40-69 Narrow · <40 None

      Narrow moat with revenue predictability as the key competitive advantage. Improving roic consistency would strengthen the moat.

      Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.
      MRNA
      17/100
      No Moat
      70+ Wide · 40-69 Narrow · <40 None

      No durable competitive advantage detected. The business shows limited evidence of pricing power, consistent returns, or capital efficiency.

      Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 5 years of fundamental data.

      Forensic Accounting

      Learn more →
      CRM
      -2.73
      Unlikely Manipulator
      Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

      M-Score Trend

      Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.
      MRNA

      Insufficient data for Beneish M-Score calculation (requires 2+ years).

      Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

      Ownership Breakdown

      Learn more →
      CRM
      Insiders 3.0%Institutions 94.3%Retail & Other 2.8%
      No. of Institutional Holders3,722
      High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.
      MRNA
      Insiders 7.3%Institutions 78.9%Retail & Other 13.7%
      No. of Institutional Holders1,044
      High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.

      High insider ownership aligns management incentives with shareholders. Institutional concentration can indicate smart-money conviction but also crowding risk.

      Insider Buying Activity

      Learn more →
      CRM
      0
      Buys (3M)
      5
      Buys (12M)
      Total value (12M): $27.38M
      ALBER LAURA
      Director
      $500,266
      @ $194.58 · 2026-03-19
      KIRK DAVID BLAIR
      Director
      $500,178
      @ $194.62 · 2026-03-18
      KIRK DAVID BLAIR
      Director
      $500,722
      @ $258.64 · 2025-12-17
      MORFIT G MASON
      Director and Beneficial Owner of more than 10% of a Class of Security
      $25.02M
      @ $260.58 · 2025-12-05
      KIRK DAVID BLAIR
      Director
      $865,827
      @ $254.66 · 2025-09-09
      Open market purchases · includes direct & indirect ownership · excludes option exercises
      MRNA
      0
      Buys (3M)
      0
      Buys (12M)
      SAGAN PAUL L
      Director
      $1.00M
      @ $31.76 · 2025-03-03
      BANCEL STEPHANE J
      Chief Executive Officer
      $5.00M
      @ $31.22 · 2025-03-03
      Open market purchases · includes direct & indirect ownership · excludes option exercises

      Open market purchases · includes direct & indirect ownership · excludes option exercises.

      Insider Selling Activity

      Learn more →
      CRM
      0
      Sells (3M)
      15
      Sells (12M)
      Total value (12M): $40.30M
      KROES NEELIE
      Director
      $929,276
      @ $238.70 · 2026-01-14
      HARRIS G PARKER
      Officer and Director
      $31.61M
      @ $234.70 · 2025-12-02
      BENIOFF MARC RUSSELL
      Chief Executive Officer
      $575,140
      @ $255.62 · 2025-10-23
      BENIOFF MARC RUSSELL
      Chief Executive Officer
      $590,102
      @ $262.27 · 2025-10-21
      BENIOFF MARC RUSSELL
      Chief Executive Officer
      $567,631
      @ $252.28 · 2025-10-20
      BENIOFF MARC RUSSELL
      Chief Executive Officer
      $550,430
      @ $244.64 · 2025-10-17
      BENIOFF MARC RUSSELL
      Chief Executive Officer
      $558,810
      @ $248.36 · 2025-10-16
      BENIOFF MARC RUSSELL
      Chief Executive Officer
      $536,322
      @ $238.37 · 2025-10-15
      BENIOFF MARC RUSSELL
      Chief Executive Officer
      $548,796
      @ $243.91 · 2025-10-14
      BENIOFF MARC RUSSELL
      Chief Executive Officer
      $1.10M
      @ $244.75 · 2025-10-13
      BENIOFF MARC RUSSELL
      Chief Executive Officer
      $547,344
      @ $243.26 · 2025-10-09
      BENIOFF MARC RUSSELL
      Chief Executive Officer
      $539,533
      @ $239.79 · 2025-10-08
      BENIOFF MARC RUSSELL
      Chief Executive Officer
      $555,001
      @ $246.67 · 2025-09-23
      BENIOFF MARC RUSSELL
      Chief Executive Officer
      $552,798
      @ $245.69 · 2025-09-19
      BENIOFF MARC RUSSELL
      Chief Executive Officer
      $545,384
      @ $242.39 · 2025-09-15
      Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives
      MRNA
      3
      Sells (3M)
      6
      Sells (12M)
      Total value (12M): $11.57M
      KLINGER SHANNON THYME
      Officer
      $173,550
      @ $50.00 · 2026-06-04
      HOGE STEPHEN
      President
      $2.58M
      @ $48.40 · 2026-05-15
      HUSSAIN SHAH ABBAS
      Director
      $264,952
      @ $46.63 · 2026-05-01
      KLINGER SHANNON THYME
      Officer
      $726,047
      @ $52.29 · 2026-03-02
      HOGE STEPHEN
      President
      $7.81M
      @ $48.84 · 2026-02-23
      HUSSAIN SHAH ABBAS
      Director
      $13,910
      @ $27.60 · 2025-12-09
      HUSSAIN SHAH ABBAS
      Director
      $8,736
      @ $28.00 · 2025-06-11
      KLINGER SHANNON THYME
      Officer
      $23,637
      @ $44.68 · 2024-12-09
      KLINGER SHANNON THYME
      Officer
      $4,849
      @ $43.29 · 2024-12-03
      HOGE STEPHEN
      President
      $13,595
      @ $43.30 · 2024-12-03
      KLINGER SHANNON THYME
      Officer
      $60,675
      @ $42.79 · 2024-11-29
      HOGE STEPHEN
      President
      $12,452
      @ $42.79 · 2024-11-29
      MOCK JAMES M
      Chief Financial Officer
      $60,761
      @ $42.79 · 2024-11-29
      HOGE STEPHEN
      President
      $12,771
      @ $46.10 · 2024-11-11
      MOCK JAMES M
      Chief Financial Officer
      $42,986
      @ $60.12 · 2024-10-07
      KLINGER SHANNON THYME
      Officer
      $40,539
      @ $73.57 · 2024-09-09
      KLINGER SHANNON THYME
      Officer
      $8,777
      @ $76.99 · 2024-09-03
      HOGE STEPHEN
      President
      $24,483
      @ $76.99 · 2024-09-03
      KLINGER SHANNON THYME
      Officer
      $12,640
      @ $78.02 · 2024-08-29
      HOGE STEPHEN
      President
      $23,408
      @ $78.03 · 2024-08-29
      MOCK JAMES M
      Chief Financial Officer
      $12,640
      @ $78.02 · 2024-08-29
      KLINGER SHANNON THYME
      Officer
      $104,722
      @ $79.39 · 2024-08-28
      MOCK JAMES M
      Chief Financial Officer
      $104,881
      @ $79.40 · 2024-08-28
      HOGE STEPHEN
      President
      $21,363
      @ $84.11 · 2024-08-12
      AFEYAN NOUBAR BOGHOS
      Director
      $1.80M
      @ $119.96 · 2024-07-31
      AFEYAN NOUBAR BOGHOS
      Director
      $1.77M
      @ $117.80 · 2024-07-24
      AFEYAN NOUBAR BOGHOS
      Director
      $1.84M
      @ $122.84 · 2024-07-17
      HOGE STEPHEN
      President
      $1.82M
      @ $121.12 · 2024-07-15
      AFEYAN NOUBAR BOGHOS
      Director
      $1.76M
      @ $117.08 · 2024-07-10
      MOCK JAMES M
      Chief Financial Officer
      $81,465
      @ $118.24 · 2024-07-08
      AFEYAN NOUBAR BOGHOS
      Director
      $1.91M
      @ $127.22 · 2024-06-26
      AFEYAN NOUBAR BOGHOS
      Director
      $2.00M
      @ $133.57 · 2024-06-18
      Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives

      Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives.

      🎭 Mr. Market's Mood

      Learn more →
      CRM
      FearGreed
      🥶Extreme Fear(18/100)

      "Mr. Market is panicking — potential buying opportunity if fundamentals are strong"

      Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.
      MRNA
      FearGreed
      😏Greed(61/100)

      "Market is optimistic — be cautious and ensure you have a margin of safety"

      Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

      Composite sentiment score based on market signals. Inspired by Buffett’s "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

      ⚖️ Buffett Signal

      Learn more →
      CRM
      Awaiting DCF Data

      The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

      DCF Margin of Safety: N/AMr. Market's Mood: Extreme Fear (18)
      MRNA
      Awaiting DCF Data

      The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

      DCF Margin of Safety: N/AMr. Market's Mood: Greed (61)
      View CRM Full AnalysisView MRNA Full Analysis

      Frequently Asked Questions: CRM vs MRNA

      Is Salesforce, Inc. or Moderna, Inc. more undervalued in 2026?

      Based on our discounted cash flow model, CRM trades at a 44.5% margin of safety (intrinsic value $274 vs. price $152), compared to MRNA's -962.8% margin of safety (intrinsic $6 vs. $64).

      Which stock has a wider economic moat, Salesforce, Inc. or Moderna, Inc.?

      CRM scores 58/100 (Narrow moat), while MRNA scores 17/100 (None moat). The moat score measures competitive advantage durability across ROIC consistency, margin stability, revenue predictability, and reinvestment efficiency.

      Is Salesforce, Inc. in financial distress?

      CRM's Altman Z-Score of 2.4 places it in the Grey zone, signaling elevated bankruptcy risk. MRNA scores 2.5 (Grey zone). The Altman Z-Score is a five-factor model that predicts insolvency within two years; scores below 1.81 indicate significant distress.

      Which company has better free cash flow, Salesforce, Inc. or Moderna, Inc.?

      Salesforce, Inc. (CRM) generates a 13.3% free cash flow yield, compared to Moderna, Inc.'s -0.1%. A higher FCF yield means the business converts more of its market value into cash that can be returned to shareholders or reinvested.

      Which stock has higher return on invested capital, Salesforce, Inc. or Moderna, Inc.?

      CRM earns 9.6% ROIC versus MRNA's -26.5%. A higher ROIC means the company generates more profit per dollar of capital employed, a hallmark of durable competitive advantage in Buffett-style analysis.

      CRM vs MRNA: Which Is the Better Buy in 2026? | SafetyMargin.io